Corcept Therapeutics

The adverse effects of excess cortisol have been Corcept’s focus since the company’s inception. Abnormal levels and release of cortisol play a role in a variety of metabolic, oncological, and psychiatric diseases, and we are currently studying a new generation of compounds that may mitigate the effects of excess cortisol. In addition to our work with mifepristone, we have developed over 300 proprietary molecules, advancing the most promising of these to the clinic to see if they can mitigate the effects of excess cortisol and the serious, sometimes life-threatening conditions that may result. All of these compounds competitively block the glucocorticoid receptor (GR), but not the progesterone receptor. Scientific literature suggests that competitive GR antagonism may have a role in treating many conditions, including post-traumatic stress disorder, mild cognitive impairment, Alzheimer’s disease, alcoholism, prostate, breast and ovarian cancer, and weight gain caused by atypical anti-psychotic medications. We are investigating several of these indications in collaboration with researchers around the world.

Type
Public
HQ
Menlo Park, US
Founded
1998
Size (employees)
103 (est)+33%
Corcept Therapeutics was founded in 1998 and is headquartered in Menlo Park, US

Corcept Therapeutics Office Locations

Corcept Therapeutics has an office in Menlo Park
Menlo Park, US (HQ)
149 Commonwealth Dr

Corcept Therapeutics Metrics

Corcept Therapeutics Financial Metrics

Revenue (2016)

$81.3 m

Revenue growth (2015-16), %

62%

Gross profit

$79.3 m

Gross profit margin (2016), %

97%

Net income (2016)

$8.1 m

Market capitalization (21-Mar-2017)

$1.1 b

Closing share price (21-Mar-2017)

$10.4

Cash (31-Dec-2016)

$51.5 m
Corcept Therapeutics's current market capitalization is $1.1 b.
Corcept Therapeutics's revenue was reported to be $81.3 m in FY, 2016 which is a 61.7% increase from the previous period.
FY, 2013FY, 2014FY, 2015FY, 2016

Revenue

$10.4 m$26.6 m$50.3 m$81.3 m

Revenue growth, %

156%89%62%

Cost of goods sold

$143 k$882 k$1.4 m$2.1 m

Gross profit

$10.2 m$25.7 m$48.9 m$79.3 m

Gross profit Margin, %

99%97%97%97%

R&D expense

$23.8 m

General and administrative expense

$31.2 m$34.9 m$45.2 m

Operating expense total

$51.9 m$54.2 m$52.4 m$71.1 m

EBIT

($41.5 m)($27.6 m)($3.4 m)$10.2 m

EBIT margin, %

(401%)(104%)(7%)13%

Interest expense

$4.5 m$3.8 m$2 m

Net Income

($46 m)($31.4 m)($6.4 m)$8.1 m
FY, 2013FY, 2014FY, 2015FY, 2016

Cash

$54.9 m$24.2 m$40.4 m$51.5 m

Accounts Receivable

Inventories

$910 k$1.4 m$642 k$2 m

Current Assets

$58.3 m$30.2 m$49 m$65.7 m

PP&E

$203 k$236 k$98 k$205 k

Total Assets

$63.1 m$34.6 m$51.9 m$68.8 m

Accounts Payable

$2.4 m$1.9 m$1.3 m$2.3 m

Current Liabilities

$12.7 m$13.6 m$20.9 m$27.4 m

Additional Paid-in Capital

$313.5 m$320.5 m$348.8 m$363.5 m

Retained Earnings

($292.6 m)($324 m)($330.4 m)($322.3 m)

Total Equity

$21 m($3.4 m)$18.5 m$41.4 m

Financial Leverage

3 x-10.2 x2.8 x1.7 x
FY, 2013FY, 2014FY, 2015FY, 2016

Net Income

($46 m)($31.4 m)($6.4 m)$8.1 m

Accounts Receivable

Inventories

($290 k)($531 k)$799 k($1.3 m)

Accounts Payable

($1.4 m)($495 k)($561 k)$965 k

Cash From Operating Activities

($37.1 m)($27.4 m)$3.1 m$18.4 m

Purchases of PP&E

($127 k)($174 k)($17 k)($194 k)

Cash From Financing Activities

($970 k)($3.1 m)$13.1 m($7.1 m)

Corcept Therapeutics Market Value History

Corcept Therapeutics Online Presence

Corcept Therapeutics Company Life

You may also be interested in